Outcome of Board meeting dated May 22, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medico Intercontinental's Board approved audited standalone and consolidated financial results for Q4 and full year ended March 31, 2026. Standalone revenue from operations was Rs 5,712.98 lakhs with net profit of Rs 218.36 lakhs, down from Rs 256.58 lakhs in the previous year. Consolidated results show revenue of Rs 7,126.69 lakhs and net profit of Rs 505.73 lakhs (restated). The company has 6 subsidiaries and 1 joint venture (Medico Lab). The Board also reappointed M/s. MJV & Co as internal auditor for FY 2026-27. Statutory auditors V Goswami & Co issued an unmodified (clean) opinion on the financial statements. The company changed its accounting policy for Medico Lab from proportionate consolidation to equity method, applied retrospectively.
Standalone profit declined ~15% year-on-year which may concern investors, though consolidated results show healthier performance. The clean audit opinion and asset growth (standalone up 15% to Rs 6,742 lakhs) are positives. The accounting policy change for joint venture is a transparency measure.